Lidiia Koludarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lidiia Koludarova has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Alina D. Nikotina
Laboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg 194064, Russia
1 shared publicationAn-Sofie Lenaerts
Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
1 shared publicationArnaud Gaudin
Queensland Brain Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia
1 shared publicationAshley J. van Waardenberg
I-Synapse PTY LTD, Cairns, Queensland, Australia
1 shared publicationBoris A. Margulis
Laboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg 194064, Russia
1 shared publicationBrendan J. Battersby
Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (10) , 2117-2141
DDHD2 provides a flux of saturated fatty acids for neuronal energy and function
Although fatty acids support mitochondrial ATP production in most tissues, neurons are believed to rely exclusively on glucose for energy. Here we show that genetic ablation of the triglyceride and phospholipid lipase Ddhd2 impairs mitochondrial respiration and ATP synthesis in cultured neurons, despite increased glycolysis. This defect arises from reduced levels of long-chain saturated free fatty acids, particularly myristic, palmitic and stearic acids, normally released in an activity-dependent manner by Ddhd2. Inhibition of mitochondrial fatty acid import in wild-type neurons similarly reduced mitochondrial respiration and ATP production. Saturated fatty acyl-coenzyme A treatment restored mitochondrial energy production in Ddhd2 knockout neurons. When provided in combination, these activated fatty acyl-CoA supplements also rescued defects in membrane trafficking, synaptic function and protein homeostasis. These findings uncover that neurons perform β-oxidation of endogenous long-chain free fatty acids to meet ATP demands and reveal a potential therapeutic strategy for hereditary spastic paraplegia 54 caused by DDHD2 mutations.
- 30 September 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (10) , 2117-2141
Open AccessDDHD2 provides a flux of saturated fatty acids for neuronal energy and function
Although fatty acids support mitochondrial ATP production in most tissues, neurons are believed to rely exclusively on glucose for energy. Here we show that genetic ablation of the triglyceride and phospholipid lipase Ddhd2 impairs mitochondrial respiration and ATP synthesis in cultured neurons, despite increased glycolysis. This defect arises from reduced levels of long-chain saturated free fatty acids, particularly myristic, palmitic and stearic acids, normally released in an activity-dependent manner by Ddhd2. Inhibition of mitochondrial fatty acid import in wild-type neurons similarly reduced mitochondrial respiration and ATP production. Saturated fatty acyl-coenzyme A treatment restored mitochondrial energy production in Ddhd2 knockout neurons. When provided in combination, these activated fatty acyl-CoA supplements also rescued defects in membrane trafficking, synaptic function and protein homeostasis. These findings uncover that neurons perform β-oxidation of endogenous long-chain free fatty acids to meet ATP demands and reveal a potential therapeutic strategy for hereditary spastic paraplegia 54 caused by DDHD2 mutations.
- Open Access
- 5 June 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (43) , 27268-27279
Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells
Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells
- 5 June 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (43) , 27268-27279
Open AccessDiscovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells
Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells Discovery and optimization of cardenolides inhibiting HSF1 activation in human colon HCT-116 cancer cells